• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 8
  3. Author

Online ISSN: 2515-8260

Volume7, Issue8

Content Analysis Of Antiallergic Drugs In The Republic Of Uzbekistan

    U.M. Tillaeva1*, Sh.Kh. Abduganiev

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 8, Pages 1275-1283

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Research objective: to study the general and individual properties of antihistamines and to conduct a content analysis of the AGs nomenclature presented in the pharmaceutical market of the Republic of Uzbekistan.
Materials and methods. The research included antihistamines nomenclature presented in the State Register of Medicinal Remedies of the Republic of Uzbekistan. The analysis involved the data on the registered medicinal remedies based on the materials of the State Register of Medicinal Remedies and Medical Devices for the period of 2018-2019. We also used data from the Vidal Reference “Medicinal remedies in Uzbekistan” and “List of Essential Medicinal Remedies”.
Results.The content analysis showed that according to the ratio of positions nomenclature of the 1st generation AGs (sedatives) by countries,both the CIS and domestic manufacturers had equal indicator values(40.5%) of registered and used AGs on the territory of the republic, whereas the foreign manufacturers proportion was about 20%. According to the data for 2019, the proportion of AGs was also equal, although we noted the increasing tendency forintroduction of the 2nd generation AGs with non-sedative effect. If 2018 was characterized by 82 names of medicinal remedies, then in 2019 this number increased to 144. Besides, we noted a total increase and use of AGs compared to 2018 for account of foreign manufacturers, which actively introduced the 2nd generation AGs. The CIS countries and domestic manufacturers lagged significantly behind, accounting for 11.3% and 22%, respectively.
Conclusion. We consider itvery promising to introduce into domestic pharmaceutical practice the 2nd generation AGs in the transdermal and soft form due to the advantages of their application.In addition, at present time, an active work is being carried out to develop and introduce gels and suppositories, combinations ofantiallergic drugs with non-steroidal anti-inflammatory drugs, synthesized by domestic scientists, for the purpose of introducing them into domestic pharmaceutical production and thus reducing the import dependency of drugs in the Republic of Uzbekistan.
Keywords:
  • PDF (219 K)
  • XML
(2020). Content Analysis Of Antiallergic Drugs In The Republic Of Uzbekistan. European Journal of Molecular & Clinical Medicine, 7(8), 1275-1283.
U.M. Tillaeva1*, Sh.Kh. Abduganiev. "Content Analysis Of Antiallergic Drugs In The Republic Of Uzbekistan". European Journal of Molecular & Clinical Medicine, 7, 8, 2020, 1275-1283.
(2020). 'Content Analysis Of Antiallergic Drugs In The Republic Of Uzbekistan', European Journal of Molecular & Clinical Medicine, 7(8), pp. 1275-1283.
Content Analysis Of Antiallergic Drugs In The Republic Of Uzbekistan. European Journal of Molecular & Clinical Medicine, 2020; 7(8): 1275-1283.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 151
  • PDF Download: 265
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus